Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study [Hematologic Malignancy]
Conclusion
Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Sehn, Goy, Offner, Martinelli, Caballero, Gadeberg, Baetz, Zelenetz, Gaidano, Fayad, Buckstein, Friedberg, Crump, Jaksic, Zinzani, Padmanabhan Iyer, Sahin, Chai, Fingerle-Rowson, Press Tags: Biologic Therapy Hematologic Malignancy Source Type: research
More News: Cancer & Oncology | Cough | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan | Study